Engineered immune cells take aim at Hard-to-Treat blood cancer

NCT ID NCT03602612

Completed Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new gene therapy for multiple myeloma, a blood cancer that often becomes resistant to standard treatments. Researchers took participants' own immune T cells, modified them in the lab to recognize a protein called BCMA on myeloma cells, and infused them back after a short course of chemotherapy. The main goal was to find a safe dose and identify side effects in 35 adults whose myeloma had not been controlled by prior therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-BCMA CAR T cells
What this could lead to: If it works, this could point toward a new treatment option for multiple myeloma that has stopped responding to standard therapies.
What could go wrong: This is an early phase 1 trial with only 35 participants, so safety and effectiveness are not yet proven. There is a risk of severe side effects, including life-threatening toxicities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOMA MULTIPLE MYELOMA, PLASMA-CELL

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.